Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP3 | P08254 | 3/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058379 | 1.00 | MAOA (0.46) | MAOAMAOBMTNR1AMTNR1BKIF11 | |
| SCHEMBL554680 | 0.84 | MAOA (0.50) | MAOAMAOBMTNR1AMTNR1BCYP1A2 | |
| SCHEMBL554681 | 0.84 | MAOA (0.50) | MAOAMAOBMTNR1AMTNR1BCYP1A2 | |
| SCHEMBL5856617 | 0.82 | FFAR1 (0.44) | MAOAMAOBMTNR1AMTNR1BPPARG | |
| SCHEMBL10175128 | 0.79 | MAOA (0.55) | MAOAMAOBMTNR1AMTNR1BCYP1A2 | |
| SCHEMBL25236742 | 0.78 | MAOA (0.53) | MAOAMAOBMTNR1AMTNR1BCYP1A2 | |
| SCHEMBL25274884 | 0.78 | MAOA (0.53) | MAOAMAOBMTNR1AMTNR1BCYP1A2 | |
| SCHEMBL2295757 | 0.78 | EPHX1 (0.48) | MMP2SLC7A5CA2CA9 | |
| SCHEMBL901961 | 0.78 | EPHX1 (0.48) | MMP2SLC7A5CA2CA9 | |
| SCHEMBL901994 | 0.78 | EPHX1 (0.48) | MMP2SLC7A5CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882439-B1 | APOPTOSIS-INDUCING AGENTS | ABBVIE INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2882439-A1 | APOPTOSIS-INDUCING AGENTS | AbbVie Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| US-8883784-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140073640-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2014-03-13 | — | — | US | disclosed |
| WO-2014028381-A1 | APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073640-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | MAOA 4359/4885MAOB 3988/4885MTNR1A 3837/4885 |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | MAOA 3674/4885MAOB 1408/4885MTNR1A 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.